Innovative therapeutics

Investors

BioMarin to Attend Upcoming Investor Conferences
- Citi's 12th Annual Biotech Conference on September 6 in Boston
- Baird's 2017 Global Healthcare Conference on September 7 in New York
- Morgan Stanley 15th Annual Global Healthcare Conference on September 12 in New York
Aug 15, 2017

SAN RAFAEL, Calif., Aug. 15, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will participate in Citi's Annual Biotech Conference on September 6, 2017 in Boston, Baird's 2017 Global Healthcare Conference on September 7, 2017 in New York and the Morgan Stanley 15th Annual Global Healthcare Conference on September 12, 2017 in New York.  For information about webcasting, please visit the investor section of the BioMarin website, www.biomarin.com. A replay of all webcasts will also be archived on the site for at least one week following each event.

BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates.  

For additional information, please visit www.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.

Contacts:


Investors

Media

Traci McCarty

Debra Charlesworth

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 455-7558

(415) 455-7451

 

SOURCE BioMarin Pharmaceutical Inc.


BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information